This is a phase I trial for patients with Myelofibrosis. Study agent is arsenic trioxide produced by Cephalon, Inc. and ascorbic acid.
The specific purpose of this study is to: determine the highest dose of arsenic trioxide with or without ascorbic acid (Vitamin C) that may be given safely; compare effects, both good and bad, of arsenic trioxide with or without ascorbic acid (Vitamin C) ; test whether arsenic trioxide with or without ascorbic acid (Vitamin C) helps to treat your myelofibrosis
This is a phase I study. A phase I study tests the safety and possible effectiveness, determines a safe dose range and identifies side effects of an investigational drug.
You will receive the investigational drug in 28 day cycles. Arsenic trioxide with or without ascorbic acid (vitamin C) will be taken daily for 21 days, by mouth with orange juice. After 21 days, there will be a resting period of 7 days. This will complete a 28 day cycle. If you are assigned to an ascorbic acid (vitamin C) group, you will also take ascorbic acid (vitamin C) by mouth at 1000 mg per day for 21 days immediately after taking the dose of arsenic trioxide. After 21 days there will be a resting period of 7 days. If you complete 6 months of treatment, you will be eligible to continue treatment if your doctor feels it will benefit you, and if drug is available.
We will start arsenic trioxide at a dose of 0.15mg/kg daily. This is the approved dose in acute promyelocytic leukemia (APL). There are 3 possible dose levels to be tested and each dose will be given either with or without ascorbic acid. A dose of arsenic trioxide will be given to a group of patients without ascorbic acid. If that dose is determined to be safe, the same dose will then be given with ascorbic acid to another group of patients. Doses will be increased until either the top dose of the study is reached, or severe side effects are seen at a lower dose.